DBV Technologies SA – (NASDAQ:DBVT) – Analysts at Jefferies Group issued their Q4 2017 earnings estimates for DBV Technologies in a research report issued on Thursday. Jefferies Group analyst E. Yang anticipates that the company will post earnings of ($1.14) per share for the quarter. Jefferies Group currently has a “Buy” rating and a $51.00 target price on the stock.
A number of other equities research analysts also recently issued reports on DBVT. Zacks Investment Research upgraded shares of DBV Technologies from a “hold” rating to a “buy” rating and set a $50.00 target price for the company in a report on Tuesday, August 29th. ValuEngine downgraded shares of DBV Technologies from a “hold” rating to a “sell” rating in a research note on Tuesday, September 26th. Citigroup boosted their price objective on shares of DBV Technologies from $43.00 to $57.00 and gave the stock a “buy” rating in a research note on Monday, October 2nd. Morgan Stanley reissued an “overweight” rating and set a $72.00 target price (up from $70.00) on shares of DBV Technologies in a research report on Friday, October 6th. Finally, Deutsche Bank boosted their target price on shares of DBV Technologies from $46.00 to $56.00 in a research report on Sunday, October 8th. Three equities research analysts have rated the stock with a sell rating, two have assigned a hold rating and eight have given a buy rating to the stock. The company currently has an average rating of “Hold” and an average target price of $49.63.
Hedge funds and other institutional investors have recently modified their holdings of the business. Cubist Systematic Strategies LLC purchased a new stake in DBV Technologies during the third quarter valued at about $132,000. Quantbot Technologies LP purchased a new stake in DBV Technologies during the third quarter valued at about $146,000. Commonwealth Equity Services Inc purchased a new stake in DBV Technologies during the third quarter valued at about $233,000. Dynamic Technology Lab Private Ltd purchased a new stake in DBV Technologies during the second quarter valued at about $222,000. Finally, Belpointe Asset Management LLC purchased a new stake in DBV Technologies during the third quarter valued at about $343,000. 46.92% of the stock is owned by institutional investors.
About DBV Technologies
DBV Technologies SA is a France-based clinical-stage biopharmaceutical company focused on changing the field of immunotherapy by developing a technology platform called Vaskin. The Company’s therapeutic approach is based on epicutaneous immunotherapy, or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin.
What are top analysts saying about DBV Technologies? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for DBV Technologies and related companies.